In preclinical models of MRT, rescue of INI1 or inhibition of EZH2, and lymphoma (with EZH2 activating mutations), inhibition of EZH2 leads to slowing of tumor growth and apoptosis16, 17, 18, 19, 20, 21. Here, SMARCB1 is linked to lymphoma.